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Abstract
Objective: S100A8 (calgranulin A, MRP8) and S100A9 (calgranulin B, MRP14) are calcium-
binding proteins highly expressed by activated myeloid cells and thought to be involved in the
pathogenesis of inflammatory diseases. Circulating levels of S100A8/S100A9 are elevated in both
human and experimental models of autoimmune disease, including rheumatoid arthritis (RA).
Methods: Mice deficient in S100A9 (S100A9−/−) and wild-type controls were immunized using
standard techniques for the K/BxN serum transfer or the collagen-induced arthritis (CIA) model.
Results: S100A9−/− animals, with defective expression of both S100A8 and S100A9 proteins, had
similar arthritis and histopathology to that of wild-type controls in both mouse models.
Conclusion: S100A8 and S100A9 are not essential for disease expression in either the K/BxN
serum transfer or the CIA model of inflammatory arthritis.
Rheumatoid arthritis (RA) results in a dysregulated immune response that leads to
inflammation and destruction of the synovial linings and joint structures. Crucial to this
pathophysiological process are myeloid cells, including neutrophils, monocytes, and
macrophages (1,2), which can produce proinflammatory cytokines and matrix
metalloproteinases leading to cartilage degradation and bone destruction (3). The collagen-
induced arthritis (CIA) and the K/BxN serum transfer models are two well-established mouse
models of inflammatory arthritis that share many features with RA (1,4). Both models involve
inflammatory myeloid cells, develop erosions similar to human RA, and can be used to study
the acute (K/BxN) and chronic (CIA) portions of the human disease (1,4).
The S100 group of proteins is the largest group of calcium-binding proteins within the EF-
hand homology family (5). S100A8 (calgranulin A, MRP8) and S100A9 (calgranulin B,
MRP14) are highly expressed in activated and circulating myeloid cells and form stable
heterodimers that are secreted upon stimulation (5). Increased local and systemic protein
expression has been linked to inflammatory diseases, including RA, since the 1980s (2,5,6).
Previous studies have implicated a role for S100A9/S100A8 in experimental inflammatory
arthritis models (2,7) and in human autoimmune-mediated diseases including RA (2,6),
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Sjögren's syndrome, systemic lupus erythematosus, and inflammatory bowel disease [all
reviewed in (5)].
The S100A9-deficient (S100A9−/−) mouse has undetectable protein levels of both S100A9
and S100A8 in peripheral neutrophils and monocytes/macrophages (8,9), a deficit that has been
attributed to the loss of S100A9-mediated regulation, which protects S100A8 from degradation
(10). To examine the pathogenic role of S100A8/9 in inflammatory arthritis, we tested disease
expression in S100A9−/− animals using the K/BxN and CIA models of inflammatory arthritis.
Materials and methods
Animals
C57Bl/6 and DBA-1J mice were either purchased from Jackson Laboratories (Bar Harbor, ME,
USA) or bred and cared for in the Division of Laboratory Animal Medicine (DLAM) facilities
under the approved The University of North Carolina Institutional Animal Care and Use
Committee (IACUC) protocol number 06-242.0. The S100A9-deficient mice were provided
by Dr E. Lorenz and previously generated by Dr W. Nacken and colleagues (8).
K/BxN arthritis model
Male 6-week-old mice with a homozygous deficiency in S100A9 bred >12 generations onto
the C57Bl/6 background and wild-type C57Bl/6 controls were injected on days 0 and 2 with
5 μL K/BxN serum per gram of mouse weight intraperitoneally, similar to previously published
reports (1). Mice were measured for paw swelling, represented as a change in the mean
thickness of the mouse's fore- and hindlimbs (mm) from its baseline average, and a clinical
index, which was scored by a blinded observer using the following system: 0 = normal paw;
1 = mild ankle or digit swelling; 2 = moderate swelling of the ankle±any number of digits; 3
= maximal swelling of the entire paw and digits. The maximum score per paw was 3 with a
maximum score of 12 per mouse. At experiment termination, hindlimbs were fixed (4%
paraformaldehyde), decalcified, and embedded in paraffin for histopathology.
Induction and evaluation of CIA
S100A9−/− mice and wild-type controls were bred seven generations onto the susceptible
DBA-1J background. Age-matched 8–10-week-old control and S100A9−/− mice were
immunized with adjuvant (complete Freund's on day 0 and incomplete Freund's on day 21)
+100 mg bovine type II collagen in a 0.1 mL 1:1 v/v mixture of adjuvant+collagen injected
subcutaneously into the base of the tail, similar to previously published reports (3,11). Mice
were assessed by a blinded observer for paw swelling and clinical disease until experiment
termination when hindlimbs were processed for histopathology, as described above.
Histopathology
Serial 5 μm sections of paraffin-embedded tissue were cut and stained with haematoxylin and
eosin (H&E) according to standard protocols for morphological analysis.
Data analysis
Linear mixed models (random intercept and slope) were used to determine whether significant
differences existed in the course of the disease over time (greatest order of magnitude was
three) between the S100A9-deficient mice and wild-type controls. The overall group effect
was assessed using a likelihood ratio test (LRT). Statistical analysis was performed using SAS
version 9.1.
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S100A9-deficient mice have similar disease to wild-type mice in the K/BxN serum transfer
model
K/BxN serum transfer-mediated arthritis is a passive transfer model of autoantibodies
recognizing glucose-6-phospate isomerase that leads to an acute, self-limited inflammatory
arthritis (1). In this model, S100A9−/− mice had strikingly similar disease expression as
measured by two independent criteria, paw swelling (Figure 1A) and clinical index (Figure
1B). There was no statistically significant difference between the S100A9−/− mice (n = 10)
and wild-type controls (n = 12) in paw swelling (LRT = 3.5, df = 2, p = 0.174); however, the
clinical index did have statistical significance despite extremely similar curves (LRT = 11.8,
df = 2, p = 0.003), which may have resulted from the minimal variability of this model and a
tight standard error seen between the two groups. Consequently, histopathology was compared
between S100A9−/− animals (Figure 1C) and wild-type controls (Figure 1D), and there was
no apparent difference in the presence or severity of joint damage or bony erosions.
S100A9-deficient mice have minimally increased disease compared to wild-type mice in the
CIA model
To determine whether S100A9−/− animals had a difference in a chronic, de novo inflammatory
arthritis disease model, we studied them in CIA. Of note, S100A9−/− animals (n = 18) had
mildly increased disease scores compared to wild-type controls (n = 15) in both paw swelling
(Figure 2A; LRT = 13.4, df = 4, p = 0.010) and clinical index (Figure 2B; LRT = 8.1, df = 4,
p = 0.088), but only paw swelling achieved statistical significance. However, the
histopathology between the two groups showed that there was similar joint damage and bony
erosions (Figure 2C and 2D) despite mildly different disease curves.
Discussion
The S100A9/S100A8 heterodimer has been identified in the inflamed synovial tissue of RA
patients (6), and increased levels in serum samples and synovial fluid have correlated with
disease activity (5,12). Indeed, several investigators have suggested this heterodimer as a
potential biomarker of disease activity in inflammatory arthritis and other autoimmune disease
states where myeloid cells play a crucial role (5,13).
van Lent et al recently described decreased joint inflammation and cartilage destruction from
methylated bovine serum albumin (mBSA) antigen-induced arthritis in S100A9-deficient mice
(2). Similar to our study, S100A9−/− animals were capable of developing arthritis. In addition,
outcome measures of cellular inflammation in the S100A9 −/− joints did not differ significantly
at some time points (2). The mBSA model differs from both K/BxN and CIA in that a booster
injection is administered locally into the joint, which leads to a chronic destructive localized
arthritis, whereas K/BxN is a systemic antibody transfer and CIA is a de novo-induced immune
response dependent on the H-2q haplotype (4). These technical, and perhaps other mechanistic,
differences may additionally explain the differing results observed between the mBSA model
and our studies.
Despite the absence of S100A9 or S100A8 protein expression in the S100A9−/− mouse,
myeloid cells have normal morphology, in vivo leucocyte migration, phagocytosis, and
respiratory burst (8,9). Our data also suggest that the functional roles of myeloid cells in the
K/BxN and CIA models are preserved, despite loss of S100A9/S100A8 protein levels, because
only small clinical and no histopathological differences were seen between groups. Although
statistical significance was achieved in one of two clinical measures in both arthritis models,
the disease course, similarity in joint erosions, and inherent variability of the models would
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argue that the overall disease outcome was not dramatically affected by the absence of these
two proteins.
It is possible that either compensatory or overlapping mechanisms are at play in the S100A9
−/− mouse, which could explain why larger differences were not seen between the experimental
and control groups. Specifically, S100A12, a proinflammatory calgranulin with high
expression within myeloid cells, has also been linked to RA and psoriatic arthritis (5,14).
Additionally, S100A4 is highly expressed in RA synovial tissue and synovial fluid and may
play a significant role in the pathogenesis of chronic inflammation and joint destruction (15).
Alternatively, either other proinflammatory mediators could compensate for S100A9/S100A8
deficiency or the heterodimer may play a less significant role in mouse models of inflammation
than in human disease.
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S100A9-deficient mice have a similar disease course to wild-type (WT) mice in the K/BxN
serum transfer model. The data represents 22 animals from two independent experiments. Male
6-week-old mice with a homozygous deficiency in S100A9 (S100A9−/−) (n = 10) and WT
controls (n = 12) were injected on days 0 and 2 with 5 μL K/BxN serum per gram of mouse
weight intraperitoneally. (A) Paw swelling was represented as a change in the mean thickness
of the mouse's fore- and hindlimbs (mm) from its baseline average, and there was no difference
between S100A9−/− and WT controls (LRT = 3.5, df = 2, p = 0.174). (B) Clinical disease
assessment was scored from 0 to 3 by a blinded reader (LRT = 11.8, df = 2, p = 0.003).
Representative histopathology from (C) an S100A9−/− animal and (D) a WT control shows
similar erosive disease.
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S100A9-deficient mice have minimally increased disease compared to wild-type (WT) mice
in the CIA model. The data represent 33 animals from two independent experiments. Age-
matched 8–10-week-old S100A9−/− mice (n = 18) and WT controls (n = 15) were immunized
with adjuvant (complete Freund's on day 0 and incomplete Freund's on day 21)+100 μg bovine
type II collagen. (A) Paw swelling was represented as a change in the mean thickness of the
mouse's fore- and hindlimbs (mm) from its baseline average. S100A9−/− animals had mildly
increased paw swelling compared to WT controls (LRT = 13.4, df = 4, p = 0.010). (B) Clinical
disease was also mildly increased, but this was not statistically significant (LRT = 8.1, df = 4,
p = 0.088). Representative histopathology from (C) an S100A9−/− animal and (D) a WT control
shows similar erosive disease.
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